BERLIN (Reuters) - BioNTech Chief Executive Ugur Sahin said on Monday he was confident a COVID-19 vaccine co-developed by his company would be effective against a variant of the coronavirus that has emerged in Britain.
He said on Bild TV that the German company would investigate the mutation in the coming days but that he viewed the matter with "with a degree of soberness".
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
